On July 27, 2021, the Centers for Disease Control and Prevention (CDC) updated its Interim Public Health Recommendations for Fully Vaccinated People and scaled back the relaxed masking guidelines for vaccinated individuals that it issued in May 2021.
To read the full text of this Duane Morris Alert, please visit the firm website.
A video replay of the COVID-19: Navigating Forward Webinar Series session, “Healthcare & COVID-19: From Mandatory Vaccination Issues to Telehealth Contracting,” is available.
Duane Morris will be hosting the webinar, “Healthcare & COVID-19: From Mandatory Vaccination Issues to Telehealth Contracting,” on March 16, 2021, from 1:00 p.m. to 2:00 p.m. Eastern.
This is the fifth session of the Duane Morris COVID-19: Navigating Forward Webinar Series. For more information and the registration link, please visit the firm website.
A video replay of the COVID-19: Navigating Forward Webinar Series session, “Inauguration 2021: Anticipated Government Policy Updates and Changes Regarding COVID-19 Concerns,” is available.
Duane Morris will be hosting the webinar, “Inauguration 2021: Anticipated Government Policy Updates and Changes Regarding COVID-19 Concerns,” on January 28, 2021, from 1:00 p.m. to 2:00 p.m. Eastern.
This is the first 2021 session of the Duane Morris COVID-19: Navigating Forward Webinar Series. For more information and the registration link, please visit the firm website.
The afternoon of December 1, 2020, marked an important milestone in the fight against the coronavirus pandemic. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) voted 13-1 to approve recommendations to prioritize distribution of the initial doses of COVID-19 vaccines. ACIP took an unusual step, issuing the recommendations before the FDA issues emergency use approval (EUA) of any COVID-19 vaccines so that the recommendations could assist states in developing their own vaccine distribution plans.
To read the full text of this Duane Morris Alert, please visit the firm website.
On April 9, 2020, Governor Baker issued an emergency order, mandating that insurers cover all medically necessary emergency department and inpatient services costs of COVID-19 treatment at both out-of-network and in-network hospitals and other medical facilities, without any cost to the patient, setting the OON reimbursement rate at 135% of Medicare, and prohibiting providers from balance billing. The Governor appears to have relied on § 7 of the Massachusetts emergency preparedness and response law in issuing the Order. Section 7 gives the Governor broad powers during a state of emergency, including “[r]egulation of the business of insurance and protection of the interests of the holders of insurance policies and contracts and of beneficiaries thereunder and of the interest of the public in connection therewith.”
To read the full text of this post by Duane Morris attorney Emmy Monahan, please visit the Duane Morris Health Law Blog.
On May 11, 2020, the FDA issued two new guidances for industry and investigators of drugs and biological products proposed for use against COVID-19. These two guidances, “COVID-19 Public Health Emergency: General Considerations for Pre-IND Meetings Requests for COVID-19 Related Drugs and Biological Products” and “COVID-19: Developing Drugs and Biological Products for Treatment of Prevention,” provide insight into the expectations of the FDA regarding new treatment drug development programs in the fight against COVID-19.
To read the full text of this Duane Morris Alert, please visit the firm website.
On May 6, 2020, Governor Gavin Newsom issued Executive Order No. N-62-20. The order states that employees will be presumed to have contracted COVID-19 in the course and scope of employment for purposes of workers’ compensation benefits if all of the following conditions are satisfied:
The American Thoracic Society (ATS) on April 3, 2020 published a guidance document providing several suggestions for treatment of COVID-19. The document, entitled “COVID‐19: Interim Guidance on Management Pending Empirical Evidence,” was developed by an ATS-led international task force and addresses several recently publicized potential treatment regimens.
To read the full text of this post by Duane Morris attorney Alison Rosenblum, please visit the Duane Morris Health Law Blog.
